Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy

Korean J Intern Med. 2016 May;31(3):601-4. doi: 10.3904/kjim.2014.292. Epub 2016 Mar 7.

Authors

Sun Ae Han¹, Young Min Yoon¹, Wan Soo Lee¹, Yun Sung Kim², Byung Chul Shin¹, Jong Hoon Chung¹, Hyun Lee Kim¹

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, Chosun University Medical School, Gwangju, Korea.
² Division of Rheumatology, Department of Internal Medicine, Chosun University Medical School, Gwangju, Korea.

No abstract available

Keywords: Amyloidosis; Cyclophosphamide; Juvenile idiopathic arthritis.

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / therapeutic use*
Adult
Amyloidosis / diagnosis
Amyloidosis / drug therapy*
Amyloidosis / immunology
Anti-Inflammatory Agents / therapeutic use*
Arthritis, Juvenile / complications
Arthritis, Juvenile / diagnosis
Arthritis, Juvenile / drug therapy*
Arthritis, Juvenile / immunology
Biopsy
Cyclophosphamide / therapeutic use*
Drug Therapy, Combination
Female
Glucocorticoids / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use*
Remission Induction
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / immunology

Substances

Anti-Inflammatory Agents
Glucocorticoids
Immunosuppressive Agents
Tumor Necrosis Factor-alpha
Cyclophosphamide
Adalimumab